Estrogen receptor β (ERB) belongs to a family of nuclear receptors, which function as regulators of homeostasis. There are two types of ER- ERα and ERβ, and ERs form the class I of nuclear receptors. They are normally sequestered as multi-protein complex in the cytoplasm, until activated by their ligands. It contains a DNA-binding domain, a hinge domain, and AF1 domain, and a ligand-binding domain. It has a high level of expression in normal breast cells.
Anti-ERB antibody produced in chicken is suitable for western blotting analysis at a dilution of 1:500, for tissue or cell staining at a dilution of 1:200.
生物化学的/生理学的作用
Estrogen receptor β (ERB) functions as a transcription factor, and modulates the transcription of target genes, which are components of cell cycle including cyclins and proto-oncogenes. It activates growth-inhibitory genes and thus, functions in suppressing cell proliferation. It negates the activation of anti-apoptotic genes by ERα, via 17β-estradiol. It is inactivated in breast cancer (BC), which marks an important stage in the progression of BC, in an estrogen-dependent manner. The presence of this gene is BC has prognostic value for tamoxifen-treated patients, and might also have potential as a therapeutic target. Mitochondrial ERβ2 has anti-apoptotic functions, and thus predicts poor prognosis in serous ovarian cancer.
物理的形状
Solution in phosphate buffered saline containing 0.02% sodium azide.
The role and clinical value of ERβ1 expression is controversial and recent data demonstrates that many ERβ antibodies are insensitive and/or non-specific. Therefore, we sought to comprehensively characterize ERβ1 expression across all sub-types of breast cancer using a validated antibody
We previously showed an unfavorable prognostic role of the cytoplasmic estrogen receptor β2 (cERβ2) in serous ovarian cancer. Here we aimed to investigate molecular determinants in cell survival function of cERβ2 in this malignant disease. We used immunohistochemistry to evaluate
Estrogen receptor β (ERβ) is a member of the nuclear receptor family of homeostatic regulators that is frequently lost in breast cancer (BC), where its presence correlates with a better prognosis and a less aggressive clinical outcome of the disease.